Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1Depression 1

Interventions

Gemcitabine 4Cisplatin 4Rituximab 2Fluorouracil 2Everolimus 2tislelizumab 1phosphorylethanolamine 1parsaclisib 1human papillomavirus vaccine, L1 type 16, 18 1famitinib 1dalpiciclib 1Zinc Sulfate 1Zinc 1Vitamin B 6 1Tamoxifen 1Sunitinib 1Sorafenib 1Radiotherapy, Adjuvant 1Pyridoxine 1Proton Pump Inhibitors 1Prednisone 1Platelet Transfusion 1Photochemotherapy 1Pemetrexed 1Patient Portals 1Paclitaxel 1Oxaliplatin 1Neoadjuvant Therapy 1N-hydroxy-4-acetylaminostilbene 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER_GOV × Duloxetine Hydrochloride × Clear all
NCT02443194 2015-12-03

The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Tel-Aviv Sourasky Medical Center

Phase 3 Terminated
50 enrolled
CNS

Depression, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡